Reimbursed Orphan Medicines in Bulgaria and the Share of Biotechnology-Derived Products-Reference-Cited by-同舟云学术

Reimbursed Orphan Medicines in Bulgaria and the Share of Biotechnology-Derived Products

Published:2011-01 Issue:2 Volume:25 Page:2418-2423
ISSN:1310-2818
Container-title:Biotechnology & Biotechnological Equipment
language:en
Short-container-title:Biotechnology & Biotechnological Equipment

Author:

Stoimenova Assena,Manova Manoela,Savova Alexandra,Angelovska Bistra,Petrova Guenka

Publisher

Informa UK Limited

Subject

Biotechnology

Link

http://www.tandfonline.com/doi/pdf/10.5504/BBEQ.2011.0043

Reference35 articles.

1. Networking for rare diseases: a necessity for Europe

2. Les médicaments orphelins commercialisés en France (2001-2005) : information officielle et spécificités

3. Bulgarian Health Act (2004) State Gazette &70/10 Aug. 2004.

4. Bulgarian Law on Medicinal Products in Human Medicine (2007) State Gazette &31/13 Apr. 2007.

5. Bulgarian National Plan for Rare Diseases (2009–2013) (genetic, birth defects and noninherited diseases), Ministry of Health, Republic of Bulgaria.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and economic assessment of nusinersen: the Bulgarian perspective;Expert Opinion on Orphan Drugs;2020-10-02

2. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries;Frontiers in Pharmacology;2018-07-20

3. Benefits of investment into modern medicines in Central–Eastern European countries;Expert Review of Pharmacoeconomics & Outcomes Research;2013-12-19

4. A Cross-Country Comparison of Reimbursed Orphan Medicines in Bulgaria, Greece and Romania;Biotechnology & Biotechnological Equipment;2013-01

5. An Insight on Differences in Availability and Reimbursement of Orphan Medicines Among Serbia, Bulgaria and Sweden;Biotechnology & Biotechnological Equipment;2012-01